Germline Testing in Patients with Breast Cancer
Publication Date: January 4, 2024
Last Updated: January 4, 2024
Treatment
Recommendation 1.1
All patients newly diagnosed with breast cancer with stage I–III or de novo stage IV/metastatic disease who are 65 years of age or younger at diagnosis should be offered BRCA1/2 testing. (CB, , , )
1048203
Recommendation 1.2
All patients newly diagnosed with breast cancer with stage I–III or de novo stage IV/metastatic disease who are older than age 65 should be offered
BRCA1/2 testing if:
- they are candidates for poly (ADP-ribose) polymerase (PARP) inhibitor therapy for early-stage or metastatic disease,
- they have triple-negative breast cancer,
- their personal or family history suggests the possibility of a pathogenic variant,
- they were assigned male sex at birth,
- they are of Ashkenazi Jewish ancestry or are members of a population with an increased prevalence of founder mutations.
(CB, , , )1048203
Recommendation 1.3
Patients undergoing BRCA1/2 testing should also be offered testing for other cancer predisposition genes as suggested by their personal or family history. Consultation with a provider experienced in clinical cancer genetics can help guide this decision-making and should be made available to patients when possible. (CB, , , )
1048203
Recommendation 2.1
All patients with recurrent breast cancer (local or metastatic) who are candidates for PARP inhibitor therapy should be offered BRCA1/2 testing regardless of family history. (CB, , , )
Qualifying statement: Small single-arm studies show that oral PARP inhibitor therapy demonstrates high response rates in women with metastatic breast cancer and germline pathogenic variants in PALB2.
1048203
Recommendation 2.2
BRCA1/2 testing should be offered to patients with a second primary cancer either in the contralateral or ipsilateral breast. (CB, , , )
1048203
Recommendation 3.1
All patients with a personal history of breast cancer diagnosed at or before age 65 years who are without active disease should be offered BRCA1/2 testing if the result will inform personal risk management or family risk assessment. (CB, , , )
1048203
Recommendation 3.2
All patients with a personal history of breast cancer diagnosed over age 65 with no active disease, who meet one of the following criteria, should be offered
BRCA1/2 testing if the result will inform personal risk management or family risk assessment:
- their personal or family history suggests the possibility of a pathogenic variant,
- they were assigned male sex at birth,
- they had triple-negative breast cancer,
- they are of Ashkenazi Jewish ancestry or are members of a population with an increased prevalence of founder mutations.
(CB, , , )1048203
Recommendation 4.1
Testing for high penetrance genes beyond BRCA1/2, including PALB2, TP53, PTEN, STK11, and CDH1, could inform medical therapy, influence surgical decision making, refine estimates of risks of second primary cancer, and inform family risk assessment, and thus should be offered to appropriate patients. (CB, , , )
1048203
Recommendation 4.2
Testing for moderate penetrance breast cancer genes currently offers no benefits for treatment of the index breast cancer but may inform risks of second primary cancer or family risk assessment, and thus may be offered to appropriate patients who are undergoing BRCA1/2 testing. (CB, , , )
1048203
Recommendation 4.3
If a multi-gene panel is ordered, the specific panel chosen should take into account the patient’s personal and family history. Consultation with a provider experienced in clinical cancer genetics can be helpful in selecting a specific multi-gene panel or interpreting its results and should be made available to patients when possible. (CB, , , )
1048203
Recommendation 5.1
Patients undergoing genetic testing should be given sufficient information before testing to provide informed consent. (CB, , , )
1048203
Recommendation 5.2
Patients with pathogenic variants should be provided with individualized post-test genetic counseling and offered referral to a provider experienced in clinical cancer genetics. (CB, , , )
1048203
Recommendation 5.3
Variants of uncertain significance should not alter management. Patients should be made aware that variants of uncertain significance may be reclassified as being pathogenic, and they should understand that periodic follow up is necessary. Consultation with a provider experienced in clinical cancer genetics can be helpful and should be made available to patients when possible. (CB, , , )
1048203
Recommendation 5.4
Patients without a pathogenic variant on genetic testing may still benefit from counseling, if there is a significant family history of cancer, and referral to a provider experienced in clinical cancer genetics is recommended. (CB, , , )
1048203
The information in this patient summary should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.
Title
Germline Testing in Patients with Breast Cancer
Authoring Organizations
American Society of Clinical Oncology
Society of Surgical Oncology
Publication Month/Year
January 4, 2024
Last Updated Month/Year
March 14, 2024
Country of Publication
US
Target Patient Population
Patients with breast cancer
Target Provider Population
Oncologists, surgeons
Inclusion Criteria
Male, Female, Adult, Older adult
Health Care Settings
Ambulatory, Outpatient
Intended Users
Genetics, nurse, nurse practitioner, physician, physician assistant
Scope
Counseling, Treatment
Diseases/Conditions (MeSH)
D001943 - Breast Neoplasms, D005817 - Genetic Counseling, D006580 - Genetic Carrier Screening, D005816 - Genetic Complementation Test, D005819 - Genetic Markers, D020022 - Genetic Predisposition to Disease
Keywords
breast cancer, Germline Testing, BRCA1, BRCA2, BRCA 1/2 testing
Source Citation
Bedrosian I, et al. Germline Testing in Patients with Breast Cancer: ASCO-SSO Guideline. J Clin Oncol. 2024 Jan 04. doi: 10.1200/JCO.23.02225
Methodology
Number of Source Documents
102
Literature Search Start Date
September 20, 2012
Literature Search End Date
January 12, 2023